Gomez-Paz Sandra, Lam Eric, Gonzalez-Mosquera Luis, Berookhim Brian, Mustacchia Paul, Fogel Joshua, Rubinstein Sofia
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nassau University Medical Center, New York, USA.
Department of Internal Medicine, Nassau University Medical Center, New York, USA.
Int J Crit Illn Inj Sci. 2022 Oct-Dec;12(4):222-228. doi: 10.4103/ijciis.ijciis_29_22. Epub 2022 Dec 26.
The Acute Physiologic and Chronic Health Evaluation II (APACHE-II), Sequential Organ Failure Assessment (SOFA), and Model for End-Stage Liver Disease modified for Sodium concentration (MELD-Na) scores are validated to predict disease mortality. We studied the prognostic utility of these scoring systems in critically ill coronavirus disease 2019 (COVID-19) patients with liver injury.
This was a retrospective study of 291 confirmed COVID-19 and liver injury patients requiring intensive care unit level of care. These patients required supplemental oxygen requirement with fraction of inspired oxygen >55% and/or the use of vasopressor. MELD-Na, SOFA, and APACHE-II scores were adjusted. Outcomes were mortality and length of stay (LOS).
SOFA (odds ratio: 0.78, 95% confidence interval: 0.63-0.98, < 0.05) was associated with decreased odds for mortality. APACHE-II and MELD-Na were not associated with mortality or LOS.
We suggest that the novel nature of COVID-19 necessitates new scoring systems to predict outcomes in critically ill COVID-19 patients with liver injury.
急性生理与慢性健康状况评估II(APACHE-II)、序贯器官衰竭评估(SOFA)以及根据钠浓度修正的终末期肝病模型(MELD-Na)评分已被证实可预测疾病死亡率。我们研究了这些评分系统在患有肝损伤的危重症2019冠状病毒病(COVID-19)患者中的预后效用。
这是一项对291例确诊的COVID-19且患有肝损伤、需要重症监护病房护理级别的患者进行的回顾性研究。这些患者需要吸入氧分数>55%的补充氧气和/或使用血管活性药物。对MELD-Na、SOFA和APACHE-II评分进行了调整。结局指标为死亡率和住院时间(LOS)。
SOFA(比值比:0.78,95%置信区间:0.63 - 0.98,P < 0.05)与死亡率降低的几率相关。APACHE-II和MELD-Na与死亡率或住院时间无关。
我们认为,COVID-19的新特性需要新的评分系统来预测患有肝损伤的危重症COVID-19患者的结局。